PCM
GPCR icon

Penserra Capital Management’s Structure Therapeutics GPCR Stock Holding History

Penserra Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83K Buy
+1,738
New +$119K ﹤0.01% 742
2025
Q2 		– Sell
-3,411
Closed -$59K – 1070
2025
Q1 		$59K Buy
3,411
+304
+10% +$7.45K ﹤0.01% 834
2024
Q4 		$84K Buy
3,107
+135
+5% +$4.79K ﹤0.01% 879
2024
Q3 		$130K Buy
2,972
+1,384
+87% +$53.5K ﹤0.01% 753
2024
Q2 		$62K Buy
+1,588
New +$65.2K ﹤0.01% 858

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Penserra Capital Management's GPCR Position: Q1 2026 in Review

Penserra Capital Management opened a new position in Structure Therapeutics (GPCR) in Q1 2026: 1,738 shares worth $83K. The stake represents ﹤0.01% of the portfolio and ranks #742 among its holdings. This is a return to the name: Penserra Capital Management previously reported a position in GPCR as recently as Q1 2025.

Penserra Capital Management first reported a position in GPCR in Q2 2024 and has held it in 5 quarters since. The position peaked at $130K in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Penserra Capital Management held 1,738 shares of Structure Therapeutics worth $83K as of Q1 2026.
  • Structure Therapeutics was a new Penserra Capital Management position in Q1 2026.
  • Structure Therapeutics made up ﹤0.01% of Penserra Capital Management's portfolio in Q1 2026, its #742 holding.
  • Penserra Capital Management first reported a position in Structure Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Penserra Capital Management's Structure Therapeutics position peaked at $130K in Q3 2024.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.